Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortCore of the WHO-preferred HIV treatment.Backbone drug for HIV treatment, PrEP and hepatitis B.
Body systemAntiviralsAntivirals
Drug classIntegrase inhibitorsNucleos(t)ide reverse transcriptase inhibitors
SupplyPrescription onlyWHO essential medicinePrescription onlyWHO essential medicine
Main usesHIV-1 treatment (with other antiretrovirals)HIV treatment, HIV pre-exposure prophylaxis (PrEP, with emtricitabine), Chronic hepatitis B
How it worksStops HIV inserting its genes into your cells' DNA.A fake DNA building block that stops HIV and hepatitis B copying themselves.
Starts working——
Half-lifeAbout 14 hoursAbout 17 hours in plasma
Typical adult dose50 mg once a day (twice a day with rifampicin or certain resistance).300 mg (245 mg tenofovir disoproxil) once a day.
FormsTablet, Dispersible tablet, Combination tablets (TLD, Triumeq, Dovato)Tablet, Combination tablets
Common side effectsHeadache, Insomnia, Weight gain, NauseaNausea, Diarrhoea, Headache, Dizziness
Serious side effectsHypersensitivity reaction (rare), Liver injury in hepatitis co-infection, Depression (rare)Kidney damage, Bone thinning, Hepatitis B flare if stopped suddenly
Don't take if——
Alcohol——
PregnancyGenerally considered safeAn early signal of neural tube defects shrank with more data; WHO recommends it for all, including in pregnancy.Generally considered safeWidely used in pregnancy for HIV and hepatitis B.
Breastfeeding——
In use since20132001
Brand namesUnited States: TivicayUnited Kingdom: TivicayAustralia: TivicayUnited States: Viread, Truvada (with emtricitabine)United Kingdom: Viread, TruvadaIndia: Tenvir
Legal status——
ATC codeJ05AJ03J05AF07

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker